ORCID as entered in ROS

Select Publications
2015, 'Quality of Life in Autoimmune Blistering Diseases', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 623 - 631, http://dx.doi.org/10.1007/978-3-662-45698-9_67
,2015, 'Rituximab and Its Use in Autoimmune Bullous Disorders', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 523 - 529, http://dx.doi.org/10.1007/978-3-662-45698-9_53
,2015, 'Special Issues in Epidermolysis Bullosa: Eyes, Hair, Nails, Teeth and Pregnancy', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 695 - 709, http://dx.doi.org/10.1007/978-3-662-45698-9_73
,2015, 'Supportive Care: Bathing, Wound Care, Nutrition, Pain and Itch Management, Psychosocial Support, Palliation', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 653 - 666, http://dx.doi.org/10.1007/978-3-662-45698-9_70
,2015, 'Tetracyclines and Their Use in Autoimmune Bullous Diseases and Epidermolysis Bullosa', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 501 - 505, http://dx.doi.org/10.1007/978-3-662-45698-9_50
,2015, 'The Pathogenesis, Assessment and Management of Pruritus in Autoimmune Bullous Diseases', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 643 - 649, http://dx.doi.org/10.1007/978-3-662-45698-9_69
,2015, 'The Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 533 - 541, http://dx.doi.org/10.1007/978-3-662-45698-9_54
,2015, 'Treatment and Prevention of Glucocorticoid-Induced Osteoporosis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 593 - 603, http://dx.doi.org/10.1007/978-3-662-45698-9_63
,2015, 'Treatment of Dermatitis Herpetiformis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 573 - 578, http://dx.doi.org/10.1007/978-3-662-45698-9_60
,2015, 'Treatment of EB Complications: Esophageal Strictures, Pseudosyndactyly, Urethral and Meatal Stenosis, and Laryngeal Stenosis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 687 - 694, http://dx.doi.org/10.1007/978-3-662-45698-9_72
,2015, 'Using Intravenous Immunoglobulins in Autoimmune Bullous Diseases', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 515 - 521, http://dx.doi.org/10.1007/978-3-662-45698-9_52
,2014, 'Pemphigus', in Evidence Based Dermatology Third Edition, pp. 552 - 560, http://dx.doi.org/10.1002/9781118357606.ch65
,2011, 'Erythema Multiforme, Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis', in Harper S Textbook of Pediatric Dermatology Volume 1 Thrid Edition, pp. 78.1 - 78.8, http://dx.doi.org/10.1002/9781444345384.ch78
,2011, 'Diagnosis and Prevention of Bullous Diseases', in Preventive Dermatology in Infectious Diseases, Springer London, pp. 53 - 73, http://dx.doi.org/10.1007/978-0-85729-847-8_6
,2009, 'The Cochrane Skin Group', in Evidence Based Dermatology Second Edition, pp. 20 - 25, http://dx.doi.org/10.1002/9781444300161.ch4
,2003, 'Interventions for bullous pemphigoid', in The Cochrane Library, John Wiley & Sons, UK
,2003, 'Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita (Cochrane Review)', in Cochrane Database of Systematic Reviews, John Wiley & Sons Ltd, England
,2003, 'The Cochrane Skin Group', in Williams H; Bigby M; Diepgen T; Herxheimer A; Naldi L; Rzany B (ed.), Evidence-based Dermatology, BMJ Publishing Group, London, UK, pp. 24 - 32
,2025, 'Author Correction: Bullous pemphigoid (Nature Reviews Disease Primers, (2025), 11, 1, (12), 10.1038/s41572-025-00595-5)', Nature Reviews Disease Primers, 11, http://dx.doi.org/10.1038/s41572-025-00605-6
,2025, 'Bullous pemphigoid', Nature Reviews Disease Primers, 11, http://dx.doi.org/10.1038/s41572-025-00595-5
,2025, 'Morgellons disease: a review on current evidence and the need for consensus, standardized criteria, and future randomized controlled trials', Archives of Dermatological Research, 317, http://dx.doi.org/10.1007/s00403-025-04308-6
,2025, 'Space Oncology: A Comprehensive Scoping Review.', Wilderness Environ Med, pp. 10806032251349442, http://dx.doi.org/10.1177/10806032251349442
,2025, 'Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up).', Br J Dermatol, http://dx.doi.org/10.1093/bjd/ljaf236
,2025, 'Colchicine as a treatment option for inherited epidermolysis bullosa', Clinical and Experimental Dermatology, 50, pp. 1238 - 1240, http://dx.doi.org/10.1093/ced/llaf016
,2025, 'Dermatologic manifestations of hereditary hemochromatosis: A systematic review', Journal of the European Academy of Dermatology and Venereology, 39, pp. 976 - 986, http://dx.doi.org/10.1111/jdv.20098
,2025, 'Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnaires', Journal of Dermatology, 52, pp. 812 - 830, http://dx.doi.org/10.1111/1346-8138.17707
,2025, 'Leveraging space innovations for cancer breakthroughs on Earth', Trends in Cancer, 11, pp. 433 - 440, http://dx.doi.org/10.1016/j.trecan.2025.02.003
,2025, 'The development and validation of an investigator global assessment score for keratosis pilaris', Journal of the European Academy of Dermatology and Venereology, 39, pp. e350 - e352, http://dx.doi.org/10.1111/jdv.20326
,2025, 'Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece', Jid Innovations, 5, http://dx.doi.org/10.1016/j.xjidi.2024.100339
,2025, 'Assessment of a Real-Time PCR Assay for the Detection of Dermatophytosis by Sampling With an Adhesive Tape Technique', Australasian Journal of Dermatology, 66, pp. e60 - e61, http://dx.doi.org/10.1111/ajd.14415
,2025, 'Ethics of publication mills and payment for guaranteed authorships', Journal of the American Academy of Dermatology, 92, pp. 666 - 667, http://dx.doi.org/10.1016/j.jaad.2024.10.034
,2025, 'Toward gender equity for all members of the academic dermatology community', Clinics in Dermatology, 43, pp. 248 - 250, http://dx.doi.org/10.1016/j.clindermatol.2025.01.004
,2025, 'Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy', Journal of the European Academy of Dermatology and Venereology, 39, pp. 340 - 349, http://dx.doi.org/10.1111/jdv.20149
,2025, 'Body image disturbance has severe psychosocial impacts in patients suffering from autoimmune blistering diseases', Journal of the European Academy of Dermatology and Venereology, 39, pp. 253 - 254, http://dx.doi.org/10.1111/jdv.20491
,2025, 'Bullous pemphigoid burden of disease, management and unmet therapeutic needs', Journal of the European Academy of Dermatology and Venereology, 39, pp. 290 - 300, http://dx.doi.org/10.1111/jdv.20313
,2025, 'Pilot Study of Tildrakizumab in the Treatment of Stable Non-Segmental Vitiligo', JEADV Clinical Practice, http://dx.doi.org/10.1002/jvc2.70113
,2025, 'Quality-of-Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes and External Experts', International Journal of Dermatology, http://dx.doi.org/10.1111/ijd.17668
,2025, 'Using Biologics to Reduce Long-Term Corticosteroid Use in Pyoderma Gangrenosum: Real-World Evidence From Two Centres', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14532
,2024, 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council', British Journal of Dermatology, 192, pp. 135 - 143, http://dx.doi.org/10.1093/bjd/ljae342
,2024, '“Quality of Life in Epidermolysis Bullosa” and “Epidermolysis Bullosa Burden of Disease”: Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires', Italian Journal of Pediatrics, 50, http://dx.doi.org/10.1186/s13052-024-01657-2
,2024, 'Digital twins in dermatology, current status, and the road ahead', Npj Digital Medicine, 7, http://dx.doi.org/10.1038/s41746-024-01220-7
,2024, 'Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)', Advances in Therapy, 41, pp. 4418 - 4432, http://dx.doi.org/10.1007/s12325-024-02992-w
,2024, 'A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists', Clinics in Dermatology, 42, pp. 723 - 726, http://dx.doi.org/10.1016/j.clindermatol.2024.05.008
,2024, 'Establishing minimal clinically important differences for the Pemphigus Disease Area Index', British Journal of Dermatology, 191, pp. 823 - 831, http://dx.doi.org/10.1093/bjd/ljae283
,2024, 'Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial', Eclinicalmedicine, 77, http://dx.doi.org/10.1016/j.eclinm.2024.102900
,2024, 'Keratosis pilaris treatment paradigms: Assessing effectiveness across modalities', Clinical and Experimental Dermatology, 49, pp. 1105 - 1117, http://dx.doi.org/10.1093/ced/llae066
,2024, 'Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being', Australasian Journal of Dermatology, 65, pp. e145 - e155, http://dx.doi.org/10.1111/ajd.14308
,2024, 'Dermatology Journal Advisory Boards and editorial independence', Jaad International, 16, pp. 224 - 236, http://dx.doi.org/10.1016/j.jdin.2023.08.001
,2024, 'Letter to the editor in reply to “A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists”', Clinics in Dermatology, 42, pp. 526 - 527, http://dx.doi.org/10.1016/j.clindermatol.2024.07.002
,2024, 'Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study', Journal of Investigative Dermatology, 144, pp. 1762 - 1771.e6, http://dx.doi.org/10.1016/j.jid.2024.02.023
,